Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2013
12/31/2013CA2421584C Gene therapy for cardiac arrythmias
12/31/2013CA2246768C Uses of gdnf and gdnf receptor
12/28/2013CA2820371A1 Medicated particulate animal feed supplements and methods of preparation
12/27/2013WO2013192610A2 Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
12/27/2013WO2013192589A1 Antibodies targeting hiv escape mutants
12/27/2013WO2013192566A1 Itraconazole compositions and dosage forms, and methods of using the same
12/27/2013WO2013192565A2 Use of ferric citrate in the treatment of chronic kidney disease patients
12/27/2013WO2013192556A2 Salt crystals
12/27/2013WO2013192512A1 Derivatives of pyrazole-substituted amino-heteroaryl compounds
12/27/2013WO2013192506A1 Method and composition for alleviating tumor symptoms
12/27/2013WO2013192493A1 Nanoparticles of indirubin, derivatives thereof and methods of making and using same
12/27/2013WO2013192423A2 Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
12/27/2013WO2013192388A1 Compositions and methods for regulating glucose homeostasis and insulin action
12/27/2013WO2013192367A1 Neuroendocrine tumor treatment
12/27/2013WO2013192352A1 Antibacterial agents: aryl myxopyronin derivatives
12/27/2013WO2013192350A1 Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
12/27/2013WO2013192347A1 Substituted bicyclic cycloalkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
12/27/2013WO2013192346A1 Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors
12/27/2013WO2013192345A1 Complement pathway modulators and uses thereof
12/27/2013WO2013192343A1 Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors
12/27/2013WO2013192306A1 Positive allosteric modulators of mglur2
12/27/2013WO2013192301A1 Imidazo bicyclic imminium compounds as antitumor agents
12/27/2013WO2013192300A1 Curcumin derivatives for microbial biofilm destruction
12/27/2013WO2013192286A1 Iap antagonists
12/27/2013WO2013192273A1 Heteroaryl compounds and methods of use thereof
12/27/2013WO2013192250A1 Transdermal hormone replacement therapies
12/27/2013WO2013192248A1 Progesterone formulations
12/27/2013WO2013192238A2 Compositions and methods for treatment of diabetes
12/27/2013WO2013192229A1 Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds
12/27/2013WO2013192225A1 Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
12/27/2013WO2013192165A2 Compounds and methods for activating the apoptotic arm of the unfolded protein response
12/27/2013WO2013192128A1 Imidazolyl analogs as syk inhibitors
12/27/2013WO2013192125A1 Pyrazolyl derivatives as syk inhibitors
12/27/2013WO2013192109A1 Omega-3 pentaenoic acid compositions and methods of use
12/27/2013WO2013192098A1 SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
12/27/2013WO2013192097A1 Preparation, uses and solid forms of obeticholic acid
12/27/2013WO2013192091A1 Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
12/27/2013WO2013192088A1 SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
12/27/2013WO2013192078A1 Synthetic pgpg analogs, methods of preparation and methods of use
12/27/2013WO2013192046A2 Substituted picolinamide kinase inhibitors
12/27/2013WO2013192034A2 Sanitizer compositions comprising alcohol and an antimicrobial efficacy enhancer
12/27/2013WO2013191984A1 Fused thiazin-3-ones as kca3.1 inhibitors
12/27/2013WO2013191965A1 Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
12/27/2013WO2013191763A1 Compositions containing theobromine and their use in treating tooth hypersensitivity
12/27/2013WO2013191704A1 Novel cabergoline derivatives
12/27/2013WO2013191668A1 Compositions preventing hypertension comprising soluplus
12/27/2013WO2013191565A1 Antimicrobial composition and its method of use
12/27/2013WO2013191550A1 Regioselective diazotation of aminoglycosides
12/27/2013WO2013191542A1 Metabolic imprinting effects of nutrition with large lipid globules comprising milk fat and vegetable fat
12/27/2013WO2013191533A1 Metabolic imprinting effects of nutrition with large lipid globules comprising milk fat and vegetable fat
12/27/2013WO2013191459A1 Polyvalent pneumococcal polysaccharide-protein conjugate composition
12/27/2013WO2013191445A1 Pharmaceutical composition for colon cancer treatment or metastasis suppression, comprising cadherin-11 protein expression or action suppressing agent
12/27/2013WO2013191401A1 Composition for treating or preventing diseases caused by vascular permeability, containing imatinib or pharmaceutically acceptable salt thereof as active ingredient
12/27/2013WO2013191396A1 Novel compound having ability to inhibit 11β-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
12/27/2013WO2013191293A1 Pharmaceutical composition containing loxoprofen
12/27/2013WO2013191244A1 Pyridopyrimidin-4-one derivative
12/27/2013WO2013191242A1 Test method and treatment means for small cell lung cancer having poor prognosis
12/27/2013WO2013191236A1 Composition for improving and/or treating central nervous system degenerative disease
12/27/2013WO2013191223A1 Nucleic acid complex and nucleic acid-polysaccharide complex
12/27/2013WO2013191189A1 Fused heterocyclic compound
12/27/2013WO2013191188A1 Fused heterocyclic compound
12/27/2013WO2013191187A1 Adhesive preparation composition obtained by blending drug, organic solvent, lipophilic ointment base, and powder
12/27/2013WO2013191158A1 Percutaneous absorption promoter and skin patch comprising same
12/27/2013WO2013191144A1 Novel indanesulfamide derivative
12/27/2013WO2013191128A1 Skin patch
12/27/2013WO2013191113A1 Fused heterocyclic compound
12/27/2013WO2013191112A1 Fused heterocyclic compound
12/27/2013WO2013190978A1 Agent for inducing myeloid stem cells and method for inducing myeloid stem cells
12/27/2013WO2013190559A1 Improved processes for the preparation of linezolid crystalline form iii
12/27/2013WO2013190530A1 Modified galactooligosaccharides
12/27/2013WO2013190384A1 Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
12/27/2013WO2013190355A1 Oxathiazine derivatives as antibacterial and anticancer agents
12/27/2013WO2013190325A1 Thymidine for preventing neural tube defects
12/27/2013WO2013190320A1 Imidazopyridines as inhibitors of aurora kinase and/or flt3
12/27/2013WO2013190319A1 Pharmaceutically active compounds
12/27/2013WO2013190302A1 Camsylate salt
12/27/2013WO2013190301A1 Cycloalkyl ether compounds and their use as bace inhibitors
12/27/2013WO2013190300A1 Cyclohexane-1,2'-naphthalene-1',2"-imidazole compounds and their use as bace inhibitors
12/27/2013WO2013190299A1 Cyclohexane-1,2'-indene-1',2"-imidazol compounds and their use as bace inhibitors
12/27/2013WO2013190298A1 2h-imidazol-4-amine compounds and their use as bace inhibitors
12/27/2013WO2013190296A1 Transcription factor mediated programming towards megakaryocytes
12/27/2013WO2013190151A1 Pharmaceutical composition comprising fingolimod
12/27/2013WO2013190123A1 Pyrimidinone derivatives as antimalarial agents
12/27/2013WO2013190111A1 Pharmaceutical composition of moxifloxacin hydrochloride and preparation method
12/27/2013WO2013190103A1 Sialic acid derivatives
12/27/2013WO2013190098A1 Formulations for the preparation of immediate-release tablets for oral use containing low-dose mifepristone for the treatment of endometriosis, tablets thus obtained and their preparation process
12/27/2013WO2013190097A1 Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, tablets thus obtained and their preparation process
12/27/2013WO2013190068A1 Probiotic and polyphenol against neurodegeneration
12/27/2013WO2013189950A1 Dibenzofuran derivatives with antibacterial and wound-healing activity
12/27/2013WO2013189910A1 Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
12/27/2013WO2013189905A1 Pyrrolopyrazone inhibitors of tankyrase
12/27/2013WO2013189865A1 N-aryltriazole compounds as lpar antagonists
12/27/2013WO2013189864A1 N-alkyltriazole compounds as lpar antagonists
12/27/2013WO2013189862A1 Substituted pyrazole compounds as lpar antagonists
12/27/2013WO2013189847A1 Bendamustine derivatives and related compounds, and medical use thereof cancer therapy
12/27/2013WO2013189841A1 New bicyclic thiophenylamide compounds
12/27/2013WO2013189800A1 Cisatracurium and beta-cyclodextrin derivative compositions
12/27/2013WO2013189776A1 Active ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
12/27/2013WO2013189771A1 Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
12/27/2013WO2013189588A1 Heterocyclyl-substituted-phenyl derivatives for the treatment of erectile dysfunction
1 ... 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 ... 7860